Drug class
Reversible cyclooxygenase inhibitor; antiplatelet agent
Mechanism of action
Reversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 synthesis and platelet aggregation. Platelet function recovers as the drug is cleared, unlike the irreversible effect of aspirin.
General use cases
- Prevention of thromboembolic events in selected patients with cardiovascular or cerebrovascular disease under local product authorisation; indication and use relative to other antiplatelets are jurisdiction-specific.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
